{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T17:17:53Z","timestamp":1791047873718,"version":"4.1.0"},"reference-count":61,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2011,6,16]],"date-time":"2011-06-16T00:00:00Z","timestamp":1308182400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0020135","type":"journal-article","created":{"date-parts":[[2011,11,26]],"date-time":"2011-11-26T22:54:26Z","timestamp":1322348066000},"page":"e20135","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":19,"title":["Increased Sensitivity to Broadly Neutralizing Antibodies of End-Stage Disease R5 HIV-1 Correlates with Evolution in Env Glycosylation and Charge"],"prefix":"10.1371","volume":"6","author":[{"given":"Marie","family":"Borggren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Repits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasminka","family":"Sterjovski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannes","family":"Uchtenhagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa J.","family":"Churchill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Albert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnane","family":"Achour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul R.","family":"Gorry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva Maria","family":"Feny\u00f6","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Jansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2011,6,16]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"5087","DOI":"10.1128\/JVI.69.8.5087-5094.1995","article-title":"Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase.","volume":"69","author":"LM Mansky","year":"1995","journal-title":"J Virol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/rmv.472","article-title":"The host environment drives HIV-1 fitness.","volume":"15","author":"T van Opijnen","year":"2005","journal-title":"Rev Med Virol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"4813","DOI":"10.1073\/pnas.82.14.4813","article-title":"Genomic diversity of the acquired immune deficiency syndrome virus HTLV-III: different viruses exhibit greatest divergence in their envelope genes.","volume":"82","author":"BH Hahn","year":"1985","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref4","first-page":"1","article-title":"HIV-1 entry and its inhibition.","volume":"281","author":"TC Pierson","year":"2003","journal-title":"Curr Top Microbiol Immunol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1172\/JCI117560","article-title":"Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission.","volume":"94","author":"AB van't Wout","year":"1994","journal-title":"J Clin Invest"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"7478","DOI":"10.1128\/JVI.71.10.7478-7487.1997","article-title":"Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype.","volume":"71","author":"A Bjorndal","year":"1997","journal-title":"J Virol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1128\/JCM.32.2.364-370.1994","article-title":"MT-2 cell tropism as prognostic marker for disease progression in human immunodeficiency virus type 1 infection.","volume":"32","author":"A Karlsson","year":"1994","journal-title":"J Clin Microbiol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"681","DOI":"10.7326\/0003-4819-118-9-199305010-00004","article-title":"Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS.","volume":"118","author":"M Koot","year":"1993","journal-title":"Ann Intern Med"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1742-4690-7-23","article-title":"Frequent CXCR4 tropism of HIV-1 subtype A and CRF02_AG during late-stage disease - indication of an evolving epidemic in West Africa.","volume":"7","author":"J Esbjornsson","year":"2010","journal-title":"Retrovirology"},{"key":"ref10","first-page":"325","article-title":"Coreceptor usage and RANTES sensitivity of non-syncytium-inducing HIV-1 isolates obtained from patients with AIDS.","volume":"2","author":"M Jansson","year":"1999","journal-title":"J Hum Virol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1742-4690-5-28","article-title":"Evolution of DC-SIGN use revealed by fitness studies of R5 HIV-1 variants emerging during AIDS progression.","volume":"5","author":"M Borggren","year":"2008","journal-title":"Retrovirology"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.virol.2005.04.034","article-title":"Uncoupling coreceptor usage of human immunodeficiency virus type 1 (HIV-1) from macrophage tropism reveals biological properties of CCR5-restricted HIV-1 isolates from patients with acquired immunodeficiency syndrome.","volume":"337","author":"L Gray","year":"2005","journal-title":"Virology"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"15382","DOI":"10.1073\/pnas.93.26.15382","article-title":"Sensitivity to inhibition by beta-chemokines correlates with biological phenotypes of primary HIV-1 isolates.","volume":"93","author":"M Jansson","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"11807","DOI":"10.1128\/JVI.78.21.11807-11815.2004","article-title":"Coevolution of RANTES sensitivity and mode of CCR5 receptor use by human immunodeficiency virus type 1 of the R5 phenotype.","volume":"78","author":"I Karlsson","year":"2004","journal-title":"J Virol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1086\/377105","article-title":"Decreasing sensitivity to RANTES (regulated on activation, normally T cell-expressed and -secreted) neutralization of CC chemokine receptor 5-using, non-syncytium-inducing virus variants in the course of human immunodeficiency virus type 1 infection.","volume":"188","author":"FA Koning","year":"2003","journal-title":"J Infect Dis"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1086\/374650","article-title":"Increased in vitro cytopathicity of CC chemokine receptor 5-restricted human immunodeficiency virus type 1 primary isolates correlates with a progressive clinical course of infection.","volume":"187","author":"D Kwa","year":"2003","journal-title":"J Infect Dis"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1099\/vir.0.81111-0","article-title":"Selection of human immunodeficiency virus type 1 R5 variants with augmented replicative capacity and reduced sensitivity to entry inhibitors during severe immunodeficiency.","volume":"86","author":"J Repits","year":"2005","journal-title":"J Gen Virol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.virol.2008.06.014","article-title":"Primary HIV-1 R5 isolates from end-stage disease display enhanced viral fitness in parallel with increased gp120 net charge.","volume":"379","author":"J Repits","year":"2008","journal-title":"Virology"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/1742-4690-4-89","article-title":"Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS.","volume":"4","author":"J Sterjovski","year":"2007","journal-title":"Retrovirology"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.virol.2009.10.029","article-title":"Enhanced CD4+ cellular apoptosis by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with progressive HIV-1 infection.","volume":"396","author":"J Wade","year":"2010","journal-title":"Virology"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/00002030-199002000-00002","article-title":"Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera.","volume":"4","author":"J Albert","year":"1990","journal-title":"Aids"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1128\/JVI.71.5.3734-3741.1997","article-title":"Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals.","volume":"71","author":"C Moog","year":"1997","journal-title":"J Virol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1471-2148-6-28","article-title":"Population genetic estimation of the loss of genetic diversity during horizontal transmission of HIV-1.","volume":"6","author":"CT Edwards","year":"2006","journal-title":"BMC Evol Biol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1126\/science.1093137","article-title":"Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission.","volume":"303","author":"CA Derdeyn","year":"2004","journal-title":"Science"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nature01470","article-title":"Antibody neutralization and escape by HIV-1.","volume":"422","author":"X Wei","year":"2003","journal-title":"Nature"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"9339","DOI":"10.1073\/pnas.89.19.9339","article-title":"Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro.","volume":"89","author":"CF Barbas 3rd","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"10134","DOI":"10.1073\/pnas.88.22.10134","article-title":"A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals.","volume":"88","author":"DR Burton","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1126\/science.7973652","article-title":"Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody.","volume":"266","author":"DR Burton","year":"1994","journal-title":"Science"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1089\/aid.1994.10.359","article-title":"Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization.","volume":"10","author":"A Buchacher","year":"1994","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/00002030-199606000-00003","article-title":"Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5.","volume":"10","author":"M Purtscher","year":"1996","journal-title":"Aids"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1089\/aid.1994.10.1651","article-title":"A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1.","volume":"10","author":"M Purtscher","year":"1994","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"10199","DOI":"10.1128\/JVI.73.12.10199-10207.1999","article-title":"Characterization of primary isolate-like variants of simian-human immunodeficiency virus.","volume":"73","author":"JM Crawford","year":"1999","journal-title":"J Virol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"8873","DOI":"10.1128\/JVI.73.10.8873-8879.1999","article-title":"Determinants of neutralization resistance in the envelope glycoproteins of a simian-human immunodeficiency virus passaged in vivo.","volume":"73","author":"B Etemad-Moghadam","year":"1999","journal-title":"J Virol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1128\/JVI.73.5.4009-4018.1999","article-title":"Protection of Macaques against pathogenic simian\/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.","volume":"73","author":"JR Mascola","year":"1999","journal-title":"J Virol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1128\/JVI.70.2.1100-1108.1996","article-title":"Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1.","volume":"70","author":"A Trkola","year":"1996","journal-title":"J Virol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1128\/JVI.79.2.1252-1261.2005","article-title":"Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.","volume":"79","author":"MB Zwick","year":"2005","journal-title":"J Virol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"7293","DOI":"10.1128\/JVI.76.14.7293-7305.2002","article-title":"The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120.","volume":"76","author":"RW Sanders","year":"2002","journal-title":"J Virol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"7306","DOI":"10.1128\/JVI.76.14.7306-7321.2002","article-title":"The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1\u21922 mannose residues on the outer face of gp120.","volume":"76","author":"CN Scanlan","year":"2002","journal-title":"J Virol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.1128\/JVI.73.7.5294-5300.1999","article-title":"Selection for neutralization resistance of the simian\/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation.","volume":"73","author":"C Cheng-Mayer","year":"1999","journal-title":"J Virol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"7932","DOI":"10.1128\/JVI.00757-08","article-title":"Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection.","volume":"82","author":"EM Bunnik","year":"2008","journal-title":"J Virol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"9586","DOI":"10.1128\/JVI.00141-06","article-title":"Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity.","volume":"80","author":"M Sagar","year":"2006","journal-title":"J Virol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"e4505","DOI":"10.1371\/journal.pone.0004505","article-title":"International network for comparison of HIV neutralization assays: the NeutNet report.","volume":"4","author":"EM Fenyo","year":"2009","journal-title":"PLoS One"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1089\/088922202760265623","article-title":"A new cell line-based neutralization assay for primary HIV type 1 isolates.","volume":"18","author":"Y Shi","year":"2002","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1128\/JVI.69.1.101-109.1995","article-title":"Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120.","volume":"69","author":"JP Moore","year":"1995","journal-title":"J Virol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.virol.2006.09.021","article-title":"T cell line passage can select for pre-existing neutralization-sensitive variants from the quasispecies of primary human immunodeficiency virus type-1 isolates.","volume":"359","author":"ED Quakkelaar","year":"2007","journal-title":"Virology"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.1128\/JVI.69.7.4413-4422.1995","article-title":"Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates.","volume":"69","author":"N Sullivan","year":"1995","journal-title":"J Virol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"e3206","DOI":"10.1371\/journal.pone.0003206","article-title":"Net positive charge of HIV-1 CRF01_AE V3 sequence regulates viral sensitivity to humoral immunity.","volume":"3","author":"S Naganawa","year":"2008","journal-title":"PLoS One"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.virol.2007.02.011","article-title":"Escape of human immunodeficiency virus type 1 from broadly neutralizing antibodies is not associated with a reduction of viral replicative capacity in vitro.","volume":"363","author":"ED Quakkelaar","year":"2007","journal-title":"Virology"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1084\/jem.20101176","article-title":"Human anti-HIV-neutralizing antibodies frequently target a conserved epitope essential for viral fitness.","volume":"207","author":"J Pietzsch","year":"2010","journal-title":"J Exp Med"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.virol.2009.05.028","article-title":"Changing sensitivity to broadly neutralizing antibodies b12, 2G12, 2F5, and 4E10 of primary subtype B human immunodeficiency virus type 1 variants in the natural course of infection.","volume":"390","author":"EM Bunnik","year":"2009","journal-title":"Virology"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1097\/01.aids.0000189856.13817.76","article-title":"HIV-1 mutants escaping neutralization by the human antibodies 2F5, 2G12, and 4E10: in vitro experiments versus clinical studies.","volume":"19","author":"S Nakowitsch","year":"2005","journal-title":"Aids"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"8533","DOI":"10.1128\/JVI.02816-06","article-title":"Susceptibility of recently transmitted subtype B human immunodeficiency virus type 1 variants to broadly neutralizing antibodies.","volume":"81","author":"ED Quakkelaar","year":"2007","journal-title":"J Virol"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"9608","DOI":"10.1128\/JVI.00185-10","article-title":"HIV-1 gp120 determinants proximal to the CD4 binding site shift protective glycans that are targeted by monoclonal antibody 2G12.","volume":"84","author":"MJ Duenas-Decamp","year":"2010","journal-title":"J Virol"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1097\/00002030-199110000-00003","article-title":"Polymerase chain reaction, virus isolation and antigen assay in HIV-1-antibody-positive mothers and their children.","volume":"5","author":"G Scarlatti","year":"1991","journal-title":"Aids"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2174\/1570162052772951","article-title":"Pathogenesis of macrophage tropic HIV-1.","volume":"3","author":"PR Gorry","year":"2005","journal-title":"Curr HIV Res"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/jhered\/92.4.371","article-title":"DAMBE: software package for data analysis in molecular biology and evolution.","volume":"92","author":"X Xia","year":"2001","journal-title":"J Hered"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/bioinformatics\/bti770","article-title":"The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling.","volume":"22","author":"K Arnold","year":"2006","journal-title":"Bioinformatics"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1107\/S0907444904019158","article-title":"Coot: model-building tools for molecular graphics.","volume":"60","author":"P Emsley","year":"2004","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nature07159","article-title":"Molecular architecture of native HIV-1 gp120 trimers.","volume":"455","author":"J Liu","year":"2008","journal-title":"Nature"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/prot.20660","article-title":"Very fast empirical prediction and rationalization of protein pKa values.","volume":"61","author":"H Li","year":"2005","journal-title":"Proteins"},{"issue":"2","key":"ref61","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1021\/ct100578z","article-title":"PROPKA3: Consistent Treatment of Internal and Surface Residues in Empirical pKa predictions.","volume":"7","author":"MH Olsson","year":"2011","journal-title":"J Chem Theory Comput"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0020135","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,28]],"date-time":"2020-06-28T01:36:26Z","timestamp":1593308186000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0020135"}},"subtitle":[],"editor":[{"given":"Mario A.","family":"Ostrowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2011,6,16]]},"references-count":61,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2011,6,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0020135","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,16]]}}}